Arthritis Care & Research on June 16 epublished guidelines from the American College of Rheumatology (ACR) and American Association of Hip and Knee Surgeons (AAHKS) on perioperative management of antirheumatic medication for patients with rheumatic diseases, such as rheumatoid arthritis, spondyloarthritis, juvenile idiopathic arthritis, and systemic lupus erythematosus, who undergo total hip arthroplasty (THA) or total knee arthroplasty (TKA).
The 31-member consensus panel included hip and knee replacement surgeons,
rheumatologists, and methodologists.
After reviewing the evidence on continuing antirheumatic drug therapy during the perioperative period versus discontinuing it, and hearing feedback from 11 joint replacement patients, the panel made seven recommendations for the timing and dosage of these medications, which included disease-modifying antirheumatic drugs, biologics, tofacitinib, and glucocorticoids.
Read the full guidelines at rheumatology.org, the ACR website.